Cleary Gottlieb is advising NVHL, a portfolio company of Silver Point Capital and Blackrock, in the sale of Novasep’s Pharma Solutions and Process Solutions businesses to PharmaZell, a portfolio company of Bridgepoint.
NVHL entered into exclusive negotiations with PharmaZell on September 14, 2021, aiming to create a technology-driven leader for complex small molecules.
Novasep is a leading CDMO player, developing and manufacturing complex small molecules predominantly for pharma and biotech customers. The company leverages a wide range of differentiated technologies including high energy and cryogenic chemistries and industrial scale chromatography. It is a world leader in ADC and HPAPI, fast-growing targeted cancer therapy segments.
PharmaZell is a German producer of highly resilient and specialty APIs.
The combined business would generate nearly €500 million in revenue and employ close to 2,000 employees across 9 production and R&D sites in Europe (Germany, France, and Italy) and India.
The transaction is subject to the completion of the required information and consultation process of the relevant French works councils, as well as customary conditions precedent with respect to antitrust and foreign direct investment regulations.